Expression of mesothelin in thymic carcinoma and its potential therapeutic significance.

ABSTRACT:

Objectives

Advanced thymic epithelial tumors (TETs) lack adequate treatment options in part due to absence of well characterized tumor-specific antigens. Mesothelin, a cell surface antigen, has been used successfully as a target for tumor-directed therapy. We sought to determine tumor expression and serum levels of mesothelin in patients with TETs.

Patients and methods

Tissue samples were obtained from 71 patients with histologically confirmed, unresectable advanced TETs and evaluated for mesothelin expression by immunohistochemistry. The evaluation was blinded for clinical data and outcome. Mesothelin expression and its association with clinico-pathological parameters and survival were assessed.

Results

Thymic carcinoma, thymoma, and thymic neuroendocrine tumors (NET

SUBMITTER: Thomas A 

PROVIDER: S-EPMC7804607 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature